Dr. Verni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
653 N Town Center Dr
Suite 302
Las Vegas, NV 89144Phone+1 702-212-3428Fax+1 702-212-3452
Summary
- Michael Verni, MD is a Urologist based in Las Vegas, NV with a particular expertise in calculi. He completed his medical education in 1995 at George Washington University School of Medicine and Health Sciences, followed by residencies in Surgery and Urology at the University of Nebraska Medical Center College of Medicine. Dr. Verni has contributed to several published works in the field of Urology, with his most cited work being related to the transdifferentiation of human prostate cancer cells into a neuroendocrine-like phenotype. He has been a principal investigator in phase 3 clinical trials for the treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer. He has received several awards including Vegas Seven from Castle Connolly, CMS Meaningful Use Stage 1 Certification, and a Fellowship from the American College of Surgeons.
Education & Training
- University of Nebraska Medical Center College of MedicineResidency, Urology, 1998 - 2001
- University of Nebraska Medical Center College of MedicineResidency, Surgery, 1995 - 1997
- George Washington University School of Medicine and Health SciencesClass of 1995
Certifications & Licensure
- NV State Medical License 2001 - 2025
- American Board of Urology Urology
Awards, Honors, & Recognition
- Vegas Seven Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification Solution Series EHR, e-MDs, 2013
- Top MD Consumers Checkbook
- Join now to see all
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Reply by Authors.Surena F Matin, Phillip M Pierorazio, Nir Kleinmann, John L Gore, Ahmad Shabsigh
The Journal of Urology. 2022-04-01 - 34 citationsDurability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial ...Surena F Matin, Phillip M Pierorazio, Nir Kleinmann, John L Gore, Ahmad Shabsigh
The Journal of Urology. 2022-04-01 - 16 citationsPrimary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2...K. Kent Chevli, Neal D. Shore, Andrew Trainer, Angela B. Smith, Daniel Saltzstein
The Journal of Urology. 2021-08-26
Press Mentions
- Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: